L’Oréal is allegedly considering adding premium skin care brand Medik8 to its beauty portfolio.
The French beauty giant is rumoured to be the frontrunner to potentially buy the vitamin A-focused UK beauty brand, according to a new report by WWD.
The alleged acquisition would accelerate L’Oréal’s expansion into the dermocosmetics category even further.
Medik8 was founded in 2009 by Elliot Isaacs with a mission to become a global beauty expert in vitamin A.
The premium skin care brand is well established in the UK and Europe, and is currently expanding its reach in the US.
Medik8’s global revenues are expected to hit around US$115m globally this year, while sales were up 50% in 2024.
The business has invested heavily in the use of retinol alternative retinal (short for retinaldehyde) – which is a part of a group of vitamin A derivatives called retinoids – in its hero franchise Crystal Retinal.
Crystal Retinal made up 82% of the brand’s retinoid units sold in 2023 compared with just 18% of its retinol products, Daniel Isaacs, co-founder and Chief Product Officer at Medik8 previously told Cosmetics Business.
Cosmetics Business has reached out to Medik8 and L’Oréal for comment.
Related content:
- L’Oréal to launch new device offering microneedling-inspired treatments at home
- Caroline Hirons’ Skin Rocks secures investment to fuel global expansion
- L’Oréal Q1 sales top €11.73 billion despite lacklustre US performance
- Exclusive: BeautyPro doubles down on expansion goals with Skin Sapiens acquisition
- L’Oréal UK sales surpass £1.5 billion for the first time
- Rock Face secures £2.5 million to ‘strengthen’ its position in male grooming